Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.
Better Long-Term Buy: This Emerging Player or the Industry Leader? The choice between the two might come down to each investor's goals and risk tolerance.
Could This Potential Move Boost Eli Lilly's Prospects? The stock already looks unstoppable, and this move won't hurt its momentum.
The 2025 Growth Postgame: Analyzing the AI Supercycle and Preparing for the 2026 'Agentic' Pivot As the final trading days of 2025 wind down, the global investment community has entered a period of intense reflection. This year’s market was defined by a breathtaking "tale of two halves," where record-shattering rallies in semiconductor giants were nearly derailed by a mid-year geopolitical shock that reshaped the
How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (
NASDAQ: ABVX ). Following a year of stellar clinical results and a staggering 1,400% year-to-date rally, the French biotechnology firm has been officially crowned the most likely acquisition
Why Abivax Stock Was on Fire Today Investors were excited about the possibility of a buyout with a high price tag.
